Amplia Therapeutics has today released its Appendix 4C Cash Flow Report for the quarter ending 30 June 2022.
Key highlights include:
● Positive pre-IND meeting feedback received from US FDA;
● First site opened for recruitment in ACCENT Phase 2 clinical trial of AMP945 in pancreatic cancer;
● Significant progress in manufacturing and toxicology studies of AMP945.
Amplia finished the June 2022 quarter with cash of $12.7 million
Read today’s ASX release here
